新股消息 | 融泰药业拟港股上市 中国证监会要求补充说明近一年内新增股东入股价格的合理性等

Group 1 - The China Securities Regulatory Commission (CSRC) has published supplementary material requirements for overseas listing applications, specifically requesting Guangdong Rontai Pharmaceutical Co., Ltd. to clarify the reasonableness of the share price for new shareholders in the last 12 months [1] - Rontai Pharmaceutical has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor [1] - The CSRC has outlined several specific inquiries, including the need for legal opinions on the share price discrepancies, inconsistencies in the listing materials, and the company's business operations related to agricultural seeds and internet services [1][2] Group 2 - Rontai Pharmaceutical is recognized as a leading provider of out-of-hospital pharmaceutical services in China, focusing on digital marketing and supply chain solutions [3] - According to Frost & Sullivan, Rontai is the fourth largest provider of marketing and supply chain solutions in the out-of-hospital pharmaceutical market in China, and the largest for individual customer marketing and supply chain solutions [3] - The company has developed a digital precision marketing system that integrates digital business and data platforms with intelligent logistics infrastructure, enhancing market efficiency and accessibility for pharmaceutical companies [3]